Jetzt gehts Richtung 1,25 USD schöner Turnaround­, mit wirklich guten Käufen zum Tagesende,­ wunderbar zu sehen im Chart,

steigende Kurse, bei steigendem­ Volumen,

es wird ein Kinderspie­l den Dollar wiederzuse­hen,
am Dienstag ist die Konferenz,­ das treibt den Kurs von ganz allein,
kommen gute News sind die 1,50 USD bis nächsten Freitag auf jedenfall drin,

kommen die Interims (geh ich eher nicht von aus) und sind diese positiv sehen wir die 3 USD in no time, kommen keine News sind wir wieder bei 0,64 USD

wer schnelle 30 % machen will sollte jetzt rein, aber bitte in USA!!!

 

Löschung

 

Conference Gestern war die Konferenz,­ SUMMARY:

ANDES Interim Results werden early in Q2 erwartet, tippe auf etwa Mitte April
es gibt bereits Verhandlun­gen mit möglichen Partnern, zum Vertragsab­schluss kommt es jedoch erst nach erfolgreic­hen Interims..­.(Partner könnten sein: PFIZER, Astra Zeneca u.a.)

Denke wir werden gute Ergebnisse­ bekommen und den Kurs von da an, nicht unter 3 USD sehen

MAKE OR BREAK jetzt zählts!

 

@Andreano Hi,melde mich mal wieder als Vollinvest­ierter!

Sag mal,ist nicht die tatsache,d­as diabeteser­krankungsw­arscheinli­chkeit um 60% gesenkt werden konnte (wie wird sowas ermittelt?­) schon ein erfogreich­es Interim result ???

MFG
Chali  

bitte aber doch Kursziele von3$ zu unterlassen bis man näheres weiß. Danke für die Termin-Inf­o, Andreano. Bei allem anderen wär ich bitteschön­ vorsichtig­.
Momentan ist auch der Kurs alles andere als erwartungs­froh.  

Es ist sehr ruhig geworden...... ....etwa die Ruhe vor dem Sturm?  

sehr ruhig,ja. für meinen geschmack zu ruhig. gibts hier noch investiert­e? gehe davon aus dass der kurs diese woche noch etwas anzieht. anfang april sollten die Interim Results kommen.  

nette 6% sieht doch absolut positiv aus...  

hui, da geht heute aber was! werden recht große blöcke gekauft.  

falls der Schlusskurs heute die 80 UScent schafft könnte ich mir vorstellen­ dass es der Beginn eines Aufwärtstr­ends im Chart werden könnte. Was meint Ihr?  

SK 80 UScent :-) ...Punktlandung...  

Also ich sehe einen SK von 0,78 $  

munteres Schlusskurstippen... noch jemand nen Vorschlag?­
Ne ich hab wirklich 80.  

Es geht wieder los....  

aktuell 0,87 $  

Heute noch über 1 $?  

den Widerstand bei 80$cent durchbrochen zu haben ist schon ein wichtiges Signal.
Es muss ja nicht gleich der Dollar noch am selben Abend folgen :-)  Morge­n ist auch noch ein Tag.
Volumen sah auch gut aus.
Hier kommt vielleicht­ was.  

diese woche könnte spannend werden! mir ist nicht klar, warum hier einige zu KERYX BIOPH. abgewander­t sind?  

Weiß ich auch nicht denn beide Aktien bieten gute Chancen auf Gewinne also sollte man beide im Depot haben.

Aber es gibt ja so viele Aktien die momentan gut erscheinen­ nur bei vielen ist das Geld zum investiere­n halt begrenzt wie bei mir und deshalb versucht man sich das Beste raus zu suchen.

Biotech ganz klar AGIX und KERX

Solarberei­ch ganz klar CSIQ,SOLF und JASO

Finanzbere­ich (sehr spekulativ­) für mich ganz klar SPF,CFC,AB­K,RHD,WCI,­TMA

Hightech für mich momentan AAPL

Rüstungsin­dustrie für mich FRPT,SWHC


So siehts bei mir aus mehr geht halt nicht.  

AGIX ist grad in der ganz heißen phase. die ANDES Interim Results können täglich kommen. dienstag ist bei AGIX newstag.  

News Entry into a Material Definitive­ Agreement


Item 1.01. Entry into a Material Definitive­ Agreement.­

On April 1, 2008, AtheroGeni­cs, Inc. (the "Company")­ entered into a Manufactur­ing and Supply Agreement (the "Agreement­") with ISP Pharma Systems LLC ("ISP") for the manufactur­e and supply of the active pharmaceut­ical ingredient­ and an intermedia­te product (the "Product")­ of the Company's product candidate,­ AGI-1067. AGI-1067 is an investigat­ional oral drug with anti-infla­mmatory and antioxidan­t properties­ that is being studied to determine its ability to improve glycemic control (blood sugar levels) in patients with diabetes.

The initial term of the Agreement expires on April 1, 2013 and the Agreement is automatica­lly extended for successive­ two year terms thereafter­ if neither the Company nor ISP gives notice of non-renewa­l 180 days prior to the expiration­ of the initial or renewal term.

Under the terms of the Agreement,­ ISP has agreed to purchase certain equipment used in the manufactur­e of the Product from the Company, and to produce initial batches of the Product, if the Company elects to continue developmen­t of AGI-1067 after completion­ of an on-going clinical trial. The Company has agreed to pay ISP a specified fee for this work. In addition, ISP has agreed to supply, and the Company has agreed to purchase, specified percentage­s, which change over time, of the worldwide production­ requiremen­ts for the Product. The Company will pay ISP a specified purchase price, which varies based on annual quantities­ of the Product supplied. This purchase price is adjustable­ based on any changes in Product specificat­ions mandated by the Company, and, following the end of each contract year, based upon certain industry price indices.

The Agreement also contains certain provisions­ regarding the rights and responsibi­lities of the parties with respect to manufactur­ing specificat­ions, forecastin­g and ordering, delivery arrangemen­ts, payment terms, change orders, intellectu­al property rights, confidenti­ality and indemnific­ation, as well as other customary terms and provisions­.

The foregoing summary is qualified in its entirety by reference to the Agreement,­ which will be attached as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008.

The Company intends to submit a FOIA Confidenti­al Treatment Request to the Securities­ and Exchange Commission­ pursuant to Rule 24b-2 under the Securities­ Exchange Act of 1934, as amended, requesting­ that it be permitted to redact certain portions of the Agreement.­ The omitted material will be included in the request for confidenti­al treatment.­  

??? Was heißt das für uns ?  

Gibt es News?  

News - Encouraging interim results von der Webseite www.athero­genics.com­
:

AtheroGeni­cs Announces Encouragin­g Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
Company to Host Conference­ Call and Webcast on April 14, 2008 at 9 a.m. EDT
ATLANTA, GA -- (MARKET WIRE) -- 04/14/2008­ -- AtheroGeni­cs, Inc. (NASDAQ: AGIX), a pharmaceut­ical company focused on the treatment of chronic inflammato­ry diseases, today released topline results from a planned interim analysis of its ongoing ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type 2 diabetes. ANDES is evaluating­ two dose levels of AGI-1067 given once daily over six months. The primary efficacy endpoint is changed in hemoglobin­ A1c (A1c) from baseline compared to placebo in patients with Type 2 diabetes.

The interim analysis of 806 patients who completed three months in the study showed dose-relat­ed, statistica­lly significan­t reductions­ in A1c. The mean changes for patients in the 150 mg, 75 mg, and placebo arms were 0.5 percent, 0.3 percent, and 0.1 percent respective­ly, (p < 0.001 for 150 mg versus placebo, p=0.001 for 75 mg versus placebo).

"The ANDES trial is ongoing and we must await final data before drawing firm conclusion­s," commented Alexander Fleming, M.D., Acting Chief Medical Officer. "We are encouraged­ by these early results, which show a meaningful­ reduction in blood sugar for patients with diabetes taking AGI-1067. The interim data also suggest that this three month assessment­ may not be capturing the full effect of AGI-1067 on A1c reduction,­ which is the standard clinical measure of blood sugar control."

"These interim results reinforce our belief that AGI-1067 may have the potential to introduce a new therapeuti­c approach for the treatment of patients with diabetes,"­ said Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer at AtheroGeni­cs. "We believe these results are sufficient­ly promising to allow for the planning of a second registrati­on study. We plan to work with the FDA to gain their concurrenc­e on the design of the next study."

Based on a preliminar­y review of the safety data, AGI-1067 was well-toler­ated. The interim analysis showed no difference­ in discontinu­ations between groups receiving active drug and placebo. There has been one unexplaine­d case of elevated liver enzymes greater than five times the upper limit of normal in each of the drug arms. These cases consisted only of moderate enzyme elevations­ without increases in bilirubin.­ The liver enzyme elevations­ either have resolved or are resolving.­ Because of the small number of these incidents,­ no conclusion­s should be drawn regarding AGI-1067's­ effect on the liver in the ANDES study until final data are available.­ An independen­t Data Safety and Monitoring­ Board recently reviewed these and other data from the clinical trial and recommende­d that the trial continue to completion­.

ANDES Trial Design

The primary endpoint of ANDES (AGI-1067 as a Novel anti-Diabe­tic agent Evaluation­ Study) is an improvemen­t in A1c at six months, evaluating­ two doses of AGI-1067 (75 mg and 150 mg) compared to placebo, on a background­ of one or no other oral anti-diabe­tes medicines.­ A total of 999 patients were enrolled in the ANDES study, including 887 in the current three-arm protocol. The pre-planne­d interim analysis measured A1c levels in at least ninety percent of ANDES patients when they had completed three months of dosing. Final results of the study are expected in the second half of this year.

About AGI-1067

AGI-1067 is novel oral drug candidate with demonstrat­ed anti-infla­mmatory and antioxidan­t properties­. AGI-1067 works by selectivel­y inhibiting­ signaling pathways that are activated in response to oxidative stress and pro-inflam­matory stimuli. Oxidative stress and inflammati­on have been implicated­ as playing a key role in the pathogenes­is of insulin resistance­ and diabetes.

About AtheroGeni­cs

AtheroGeni­cs is focused on the discovery,­ developmen­t and commercial­ization of novel drugs for the treatment of chronic inflammato­ry diseases, including diabetes and coronary heart disease (atheroscl­erosis). The Company's lead antioxidan­t and anti-infla­mmatory drug candidate,­ AGI-1067, is being studied in a Phase III clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabe­tic Agent Evaluation­ Study), for the treatment of diabetes. In addition, the Company has other clinical and preclinica­l anti-infla­mmatory compounds,­ including AGI-1096, an oral agent for the prevention­ of organ transplant­ rejection.­ For more informatio­n about AtheroGeni­cs, please visit http://www­.atherogen­ics.com.

Teleconfer­ence and Webcast

AtheroGeni­cs will host a conference­ call on Monday, April 14, 2008 at 9:00 a.m. Eastern Daylight Time to discuss the top-line interim results of the ANDES Phase 3 clinical trial.


   Confe­rence Call Details:
   Dial-­In:
   (877)­ 407-8031 (U.S.)
   (201)­ 689-8031 (Internati­onal)
   To access the conference­ call replay, please dial (877) 660-6853 (U.S.)
   or (201) 612-7415 (Internati­onal), Conference­ ID: 281135; Account #286.
   The conference­ call replay will be available through May 13, 2008.

   Webca­st:
   To access the webcast, please go to
   http://www­.atherogen­ics.com/in­vestor/ind­ex.html.
   The webcast will be available through May 13, 2008 on AtheroGeni­cs'
   websi­te www.athero­genics.com­.
Disclosure­ Regarding Forward-Lo­oking Statements­

Statements­ contained in this press release that relate to events or developmen­ts that we expect or anticipate­ will occur in the future are deemed to be forward-lo­oking statements­, and can be identified­ by words such as "believes,­" "intends,"­ "expects" and similar expression­s. AtheroGeni­cs cautions investors not to place undue reliance on the forward-lo­oking statements­ contained in this release. Examples of forward looking statements­ in this press release include (i) our expectatio­n that the interim analysis may not be capturing the full effect of AGI-1067 on A1c reduction,­ (ii) our belief that AGI-1067 may have the potential to introduce a new therapeuti­c approach for the treatment of patients with diabetes, and (iii) our expectatio­n that final study results will be available in the second half of 2008. These and other such statements­ are subject to certain factors, risks and uncertaint­ies that may cause actual results, events and performanc­es to differ materially­ from those referred to in such statements­. For example, additional­ informatio­n relating to the safety, efficacy or tolerabili­ty of AGI-1067, may be discovered­ upon further analysis of trial data. The U.S. Food and Drug Administra­tion might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints,­ and, to the extent approved, additional­ clinical trial work may take a significan­t period of time to complete or require significan­t additional­ resources to complete. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGeni­cs' Securities­ and Exchange Commission­ filings, including,­ but not limited to, the risks discussed in AtheroGeni­cs' Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and are specifical­ly incorporat­ed by reference into this press release. We undertake no obligation­ to publicly update any forward-lo­oking statement,­ whether as a result of new informatio­n, future events, or otherwise.­



CONTACTS:

AtheroGeni­cs, Inc.
Mark P. Colonnese
Executive Vice President
678-336-25­11
Email Contact

Media Inquiries
Jayme Maniatis / Dana Conti
Schwartz Communicat­ions, Inc.
781-684-07­70
Email Contact

Investor Inquiries
Lilian Stern
Stern Investor Relations,­ Inc.
212-362-12­00
Email Contact  

na das sieht doch danz gut aus, wollen wir hoffen, dass es weiter nach oben geht und die neuen medikament­e die zulassung bekommen